Boehringer Ingelheim reports new efficacy and safety data for Pradaxa

Boehringer Ingelheim has announced new clinical data that further underlines the consistent efficacy and safety profile of its novel oral anticoagulant Pradaxa.

A pooled analysis of data from the phase III RE-COVER and RE-COVER II trials showed the 150 mg twice-daily therapy was consistent in a wide range of patients with acute deep vein thrombosis or pulmonary embolism.

Its positive effects were seen regardless of age, renal function, simultaneous use of non-steroidal anti-inflammatory drugs or low-dose acetylsalicylic acid, or the presence of cancer.

These findings further underline the advantages Pradaxa offers over warfarin and will offer reassurance to doctors and patients over the safety of the treatment.

Professor Klaus Dugi, corporate senior vice-president for medicine at Boehringer Ingelheim, said: "The data confirms the potential of Pradaxa as an effective treatment with safety benefits for a wide range of patients, including older patients and patients with a moderately impaired renal function."

Last month, the company presented a combined analysis of the RE-LY and RELY-ABLE trials, showing the benefits of Pradaxa over a period of more than six years.